Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet...
-
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that...
-
Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaperBriLife vaccine may have better neurtralizing ability against Omicron variant than first generation mRNA vaccines,...
-
ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded...
-
Neither NRx nor Jonathan Javitt accused current Relief management or board of a criminal past. The lawsuit identifies FINRA actions against Dr. Sevelraju, prior securities investigation, and civil...
-
Trial targeted to begin in the first quarter of 2022NRx is coordinating study with the US Health and Human Services Biomedical Advanced Research and Development Authority and several European...
-
New details of clinical trial for BriLife™ to be discussed during company update presentation at the H.C. Wainwright BioConnect Virtual ConferenceCompany presentation time changed to 9 AM EST on...
-
Conference Begins on January 10, 2022 RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of...
-
The Nasdaq Biotechnology Index (NBI) is a market index comprised of Nasdaq® listed Biotechnology and Pharmaceutical companies New classification is effective prior to the market open on Monday,...
-
After Review of More than 348 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Identified by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to...